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Yaws	  is	  endemic	  in	  West	  Africa,	  Southeast	  Asia	  and	  the	  Pacific.	  The	  WHO	  has	  2	  
launched	  a	  campaign	  based	  on	  mass	  treatment	  with	  azithromycin,	  to	  eradicate	  yaws	  3	  
by	  2020.	  Progress	  has	  been	  made	  towards	  achieving	  this	  ambitious	  goal,	  including	  4	  
the	  validation	  of	  point-­‐of-­‐care	  and	  molecular	  diagnostic	  tests	  and	  piloting	  of	  the	  5	  
strategy	  in	  a	  number	  of	  countries.	  There	  is	  a	  need	  to	  address	  gaps	  in	  knowledge	  to	  6	  
allow	  refinement	  of	  the	  eradication	  strategy.	  Studies	  exploring	  determinants	  of	  the	  7	  
spatial	  distribution	  of	  yaws	  are	  needed	  to	  facilitate	  completion	  of	  baseline	  mapping.	  8	  
The	  finding	  that	  Haemophilus	  ducreyi	  causes	  lesions	  similar	  to	  yaws	  is	  particularly	  9	  
important	  and	  further	  work	  is	  required	  to	  assess	  the	  impact	  of	  azithromycin	  on	  these	  10	  
lesions.	  The	  integration	  of	  diagnostic	  tests	  in	  to	  different	  stages	  of	  the	  eradication	  11	  
campaign	  requires	  evaluation.	  Finally	  studies	  to	  inform	  the	  optimum	  mass	  treatment	  12	  
strategy	  for	  sustainably	  interrupting	  transmission	  must	  be	  conducted.	  	  13	  
	  14	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Yaws,	  a	  disease	  caused	  by	  Treponema	  pallidum	  subsp.	  pertenue1,	  is	  one	  of	  the	  three	  3	  
endemic	  non-­‐venereal	  treponemal	  diseases2.	  It	  predominantly	  affects	  children	  living	  4	  
in	  poor,	  remote	  communities	  and	  results	  in	  lesions	  of	  the	  skin,	  bone	  and	  cartilage.	  5	  
Untreated,	  the	  disease	  can	  progress	  to	  cause	  destructive	  lesions	  of	  bones	  and	  6	  
cartilage.	  Previously,	  yaws	  was	  widespread	  throughout	  the	  tropics3,	  but	  a	  series	  of	  7	  
control	  efforts	  based	  on	  mass-­‐treatment,	  with	  intra-­‐muscular	  penicillin,	  and	  case	  8	  
finding	  led	  by	  WHO	  and	  UNICEF	  in	  the	  20th	  century	  is	  estimated	  to	  have	  reduced	  the	  9	  
burden	  of	  cases	  worldwide	  by	  up	  to	  95%4.	  Despite	  these	  efforts,	  regional	  incidence	  10	  
has	  rebounded	  in	  West	  and	  Central	  Africa,	  the	  Pacific	  and	  South-­‐East	  Asia,	  and	  yaws	  11	  
remains	  common	  in	  some	  of	  the	  poorest	  countries	  of	  the	  world.	  12	  
	  13	  
Momentum	  for	  a	  new	  campaign	  against	  yaws	  was	  catalysed	  by	  the	  2012	  publication	  14	  
of	  a	  study	  showing	  that	  single-­‐dose	  azithromycin	  was	  clinically	  highly	  effective	  and	  15	  
non-­‐inferior	  to	  penicillin5.	  The	  availability	  of	  a	  single-­‐dose,	  oral,	  well-­‐tolerated	  and	  16	  
proven	  treatment	  prompted	  WHO	  to	  develop	  a	  new	  strategy	  based	  on	  total	  17	  
community	  mass	  treatment	  (TCT)	  with	  azithromycin	  and	  case	  finding	  and	  targeted	  18	  
treatment	  (TTT)	  to	  eradicate	  the	  disease	  worldwide	  by	  20206.	  	  	  19	  
	  20	  
In	  the	  past	  3	  years,	  there	  have	  been	  significant	  developments	  in	  the	  tools	  available	  21	  
to	  support	  the	  WHO	  eradication	  effort.	  At	  the	  same	  time,	  key	  areas	  of	  research	  have	  22	  
been	  identified	  to	  ensure	  the	  international	  community	  can	  overcome	  some	  of	  the	  23	  
challenges	  related	  to	  delivering	  this	  goal.	  We	  briefly	  review	  recent	  major	  24	  
developments	  and	  present	  the	  priority	  research	  questions	  in	  the	  areas	  of	  25	  
epidemiology,	  diagnostics	  and	  treatment	  that	  must	  be	  addressed	  for	  the	  successful	  26	  







Epidemiology	  and	  Mapping	  (Box	  1)	  1	  
	  2	  
A	  major	  obstacle	  to	  interrupting	  yaws	  transmission	  is	  the	  paucity	  of	  information	  3	  
about	  where	  cases	  still	  occur.	  Prior	  to	  mid-­‐20th	  century	  eradication	  programmes,	  99	  4	  
countries	  were	  reported	  to	  be	  endemic	  for	  yaws3	  (Figure	  1).	  Of	  these	  countries,	  5	  
two—India	  and	  Ecuador—have	  reported	  successful	  elimination	  of	  yaws	  following	  6	  
large,	  government-­‐sponsored	  mass	  treatment	  programmes7,8.	  	  Thirteen	  countries	  7	  
are	  currently	  known	  to	  be	  endemic	  for	  yaws,	  with	  the	  major	  documented	  foci	  being	  8	  
in	  the	  Pacific,	  West	  Africa	  and	  South-­‐East	  Asia.	  For	  the	  remaining	  84	  previously-­‐9	  
endemic	  countries,	  there	  is	  limited	  information	  on	  the	  epidemiology	  of	  yaws.	  10	  
Improving	  this	  situation	  will	  require	  a	  significant	  increase	  in	  the	  scale	  and	  speed	  of	  11	  
mapping,	  but	  improved	  epidemiological	  data	  are	  vital	  to	  inform	  decisions	  about	  the	  12	  
interventions	  and	  resources	  required	  to	  successfully	  undertake	  eradication	  efforts.	  	  13	  
	  14	  
Development	  of	  a	  successful	  mapping	  strategy	  requires	  a	  number	  of	  questions	  to	  be	  15	  
answered.	  A	  key	  question	  is:	  what	  are	  the	  appropriate	  evaluation	  and	  treatment	  16	  
units	  for	  yaws?	  Experience	  with	  other	  disease	  programmes	  has	  shown	  that	  village-­‐17	  
level	  surveys	  are	  very	  labour-­‐intensive.	  Cases	  of	  yaws	  are	  known	  to	  cluster	  at	  at	  both	  18	  
the	  household	  and	  the	  village	  level9,10.	  Climatic	  factors	  such	  as	  rainfall11	  have	  been	  19	  
proposed	  to	  explain	  this	  spatial	  heterogeneity	  but	  there	  are	  limited	  data	  to	  explain	  20	  
the	  clustered	  nature	  of	  the	  disease,	  a	  greater	  understanding	  of	  which	  would	  help	  21	  
refine	  strategies	  for	  defining	  evaluation	  units.	  It	  may	  be	  necessary	  to	  undertake	  22	  
detailed	  fine-­‐scale	  mapping	  in	  some	  areas	  to	  allow	  this	  question	  to	  be	  explored	  in	  23	  
more	  detail.	  The	  current	  WHO	  eradication	  strategy	  defines	  the	  treatment	  unit	  as	  the	  24	  
endemic	  village	  or	  community6.	  	  As	  the	  eradication	  programme	  scales	  up,	  it	  is	  likely	  25	  
that	  delivering	  treatment	  at	  the	  village	  level	  will	  be	  impractical	  and	  treatment,	  in	  the	  26	  
first	  round,	  at	  a	  larger	  level	  may	  be	  more	  appropriate	  (Box	  2).	  27	  
	  28	  
Initial	  mapping	  efforts	  should	  be	  focused	  on	  the	  13	  countries	  known	  to	  be	  currently	  29	  
endemic,	  to	  inform	  local	  efforts	  to	  interrupt	  transmission	  (Table	  1).	  Mapping	  should	  30	  
also	  be	  undertaken	  in	  the	  countries	  which	  were	  formerly	  classified	  as	  endemic,	  but	  31	  
for	  which	  there	  are	  no	  current	  data.	  Creation	  of	  centralised	  systems	  for	  storing	  and	  32	  
5	  
displaying	  data	  could	  facilitate	  more	  standardised	  approaches	  to	  their	  collection	  and	  1	  
analysis,	  as	  has	  happened	  for	  other	  diseases	  such	  as	  trachoma,	  as	  well	  as	  the	  rapid	  2	  
implementation	  of	  public	  health	  interventions	  in	  regions	  or	  countries	  where	  yaws	  is	  3	  
found.	  4	  
	  5	  
Clinical	  diagnosis	  of	  yaws	  alone	  is	  unlikely	  to	  be	  reliable	  enough	  to	  inform	  6	  
eradication	  programmes12,13	  and	  there	  is	  therefore	  a	  need	  to	  develop	  a	  strategy	  7	  
integrating	  robust	  diagnostics	  such	  as	  	  point	  of	  care	  serological	  tests	  and	  new	  8	  
molecular	  tests14–18	  into	  national	  health	  systems.	  The	  case	  definition	  used	  and	  9	  
requirements	  for	  mapping	  may	  differ	  between	  the	  pre-­‐community	  mass	  treatment	  10	  
setting	  (where	  a	  less	  specific	  methodology	  may	  be	  acceptable),	  to	  a	  post-­‐mass	  11	  
treatment	  setting	  (where	  both	  high	  sensitivity	  and	  high	  specificity	  will	  be	  required	  to	  12	  
confirm	  eradication)	  (Box	  2).	  	  13	  
	  14	  
Finally,	  efforts	  should	  be	  undertaken	  to	  both	  learn	  from	  and	  integrate	  with	  other	  15	  
large	  scale	  mapping	  projects	  such	  as	  the	  Global	  Trachoma	  Mapping	  Project19	  and	  the	  16	  
Atlas	  of	  Human	  African	  Trypanosomiasis20.	  	  These	  efforts	  have	  trained	  large	  numbers	  17	  
of	  field	  staff	  to	  internationally	  recognized	  standards	  and	  developed	  standard	  18	  
platforms	  for	  data	  capture,	  analysis	  and	  sharing.	  Development	  of	  similar	  tools	  for	  19	  
mapping	  yaws	  should	  be	  a	  priority.	  Successful	  integration	  of	  yaws	  and	  trachoma	  20	  
mapping	  has	  already	  been	  accomplished	  in	  the	  Solomon	  Islands	  and	  Vanuatu9	  and	  21	  
similar	  efforts	  should	  be	  considered	  elsewhere.	  	  22	  
	  23	  
	  24	  
Diagnostics	  (Box	  1)	  25	  
	  26	  
The	  renewal	  of	  the	  yaws	  eradication	  programme	  has	  catalyzed	  advances	  in	  27	  
diagnostic	  tools	  for	  treponemal	  infections.	  The	  selection	  of	  the	  most	  appropriate	  28	  
diagnostic	  algorithm	  at	  each	  stage	  of	  the	  eradication	  effort	  will	  be	  critical	  for	  success	  29	  
of	  the	  program.	  Historically,	  clinical	  and	  serological	  diagnostics	  have	  been	  used	  at	  all	  30	  
stages	  of	  programs.	  To	  certify	  elimination,	  though	  it	  is	  likely	  that	  a	  more	  refined	  31	  
6	  
approach	  will	  be	  required	  in	  the	  post-­‐MDA	  environment	  to	  ensure	  that	  transmission	  1	  
has	  been	  interrupted.	  2	  
	  3	  
Several	  recent	  advances	  in	  yaws	  diagnostics	  may	  contribute	  to	  mapping	  and	  4	  
confirmation	  of	  elimination.	  A	  major	  focus	  has	  been	  on	  the	  validation	  of	  a	  new	  5	  
point-­‐of-­‐care	  assay	  –	  the	  Dual	  Path	  Platform	  (DPP)	  Syphilis	  Screen-­‐and-­‐Confirm	  assay	  6	  
(Chembio	  Diagnostic	  Systems,	  Inc.,	  NY,	  USA),	  which	  is	  based	  on	  simultaneous	  7	  
detection	  of	  antibodies	  to	  treponemal	  and	  non-­‐treponemal	  antigens.	  This	  point-­‐of-­‐8	  
care	  test	  has	  now	  been	  shown	  to	  be	  accurate	  for	  community	  screening	  in	  yaws-­‐9	  
endemic	  communities	  and	  for	  confirmation	  of	  clinically	  suspected	  cases16,17.	  	  10	  
Replacing	  central	  laboratory	  RPR	  testing	  with	  the	  DPP	  assay	  may	  improve	  the	  11	  
implementation	  of	  surveillance	  in	  both	  pre-­‐	  and	  post-­‐mass	  treatment	  settings.	  12	  
Whilst	  the	  DPP	  has	  demonstrated	  high	  sensitivity	  in	  strongly	  sero-­‐positive	  13	  
individuals,	  the	  sensitivity	  is	  reduced	  in	  individuals	  with	  low	  titre	  serology17.	  It	  may	  14	  
therefore	  be	  necessary	  to	  consider	  strategies	  such	  as	  repeat	  or	  confirmatory	  testing	  15	  
in	  some	  settings.	  16	  
	  17	  
A	  large-­‐scale	  surveillance	  tool	  would	  be	  useful	  to	  identify	  communities	  requiring	  18	  
focal	  mapping.	  	  To	  this	  end,	  studies	  are	  underway	  to	  validate	  serological	  testing	  for	  19	  
yaws	  on	  a	  multiplexed	  platform	  that	  could	  be	  integrated	  with	  other	  elimination	  or	  20	  
national	  health	  programs21.	  	  Ideally	  this	  would	  facilitate	  differentiation	  of	  previous	  21	  
from	  current	  infection,	  the	  latter	  of	  which,	  applied	  in	  appropriate	  age	  groups,	  might	  22	  
be	  taken	  to	  indicate	  on-­‐going	  transmission22.	  23	  
	  24	  
Subspecies-­‐specific	  molecular	  tools	  to	  accurately	  identify	  the	  presence	  or	  absence	  of	  25	  
T.	  pallidum	  subsp.	  pertenue	  and	  the	  mutations	  associated	  with	  azithromycin	  26	  
resistance	  have	  also	  become	  available14,15,18,23–26.	  Recent	  data	  showing	  that	  lesion	  27	  
exudate	  samples	  collected	  onto	  filter	  paper	  in	  the	  field	  generate	  reliable	  results,	  will	  28	  
help	  to	  overcome	  a	  major	  logistical	  obstacle	  previously	  precluding	  programmatic	  29	  
application	  of	  PCR,	  allowing	  these	  techniques	  to	  be	  used	  even	  on	  samples	  from	  the	  30	  
most	  remote	  communities	  in	  which	  yaws	  is	  found18.	  In	  addition,	  the	  development	  of	  31	  
other	  DNA-­‐based	  amplification	  techniques,	  such	  as	  a	  loop-­‐mediated	  isothermal	  32	  
7	  
amplification	  test,	  as	  a	  simple	  and	  rapid	  screening	  tool	  in	  the	  filed	  or	  at	  the	  point-­‐of-­‐1	  
care	  could	  be	  useful	  in	  low-­‐resource	  settings	  where	  a	  sophisticated	  molecular	  testing	  2	  
may	  be	  impractical.	  The	  application	  of	  molecular	  diagnostics,	  genotyping,	  and	  3	  
microbiome	  analysis	  using	  whole	  genome	  sequencing	  may	  also	  allow	  a	  more	  4	  
detailed	  understanding	  of	  the	  biology	  of	  pathogens	  in	  cutaneous	  lesions	  and	  the	  5	  
epidemiology	  of	  yaws	  that	  will	  permit	  careful	  assessment	  of	  the	  efficacy	  of	  6	  
eradication	  efforts.	  7	  
	  8	  
Instruments	  to	  differentiate	  cases	  of	  treatment	  failure	  from	  individuals	  who	  remain	  9	  
seropositive	  following	  successful	  treatment	  (serofast	  status)	  need	  to	  be	  developed.	  10	  
This	  is	  particularly	  important	  given	  the	  increasing	  recognition	  that	  other	  organisms	  11	  
may	  be	  responsible	  for	  causing	  chronic	  skin	  ulcers	  in	  yaws	  endemic	  communities12,24.	  12	  
There	  is	  no	  currently	  available	  diagnostic	  test	  shown	  to	  be	  of	  value	  for	  this	  role.	  13	  
Detection	  of	  treponemal	  DNA	  sequences	  in	  blood	  specimens	  by	  PCR	  has	  been	  14	  
achieved	  sporadically	  in	  cases	  of	  early	  syphilis27,	  but	  	  not	  in	  cases	  of	  yaws28.	  	  	  15	  
	  16	   Individuals	  who	  had	  been	  treated	  for	  clinical	  disease	  yet	  remain	  serofast	  are	  17	   likely	  to	  require	  pragmatic	  retreatment,	  possibly	  with	  an	  alternative	  agents	  such	  	  18	   as	  injectable	  penicillin.	  Assuming	  that	  treatment	  of	  these	  individuals	  has	  been	  19	  
successful	  then	  such	  cases	  will	  cease	  to	  contribute	  to	  transmission	  and	  the	  number	  20	  
of	  clinical	  cases	  should	  decline.	  As	  yaws	  can	  relapse	  for	  up	  to	  5-­‐10	  years	  surveillance	  21	  
will	  need	  to	  be	  maintained	  for	  a	  prolonged	  period	  to	  confirm	  that	  transmission	  has	  22	  
truly	  been	  interrupted.	  As	  the	  number	  of	  clinical	  cases	  declines	  the	  emphasis	  of	  23	  
surveillance	  will	  switch	  to	  serological	  surveillance	  of	  children	  aged	  5	  or	  less	  to	  detect	  24	  
the	  presence	  or	  absence	  of	  newly	  acquired	  infections.	  Use	  of	  this	  measure	  should	  25	  
avoid	  the	  complexity	  of	  dealing	  with	  serofast	  individuals.	  	  26	  
	  27	  
	  28	  
Laboratory	  capacity	  building	  is	  required	  for	  distribution	  and	  deployment	  of	  new	  29	  
diagnostic	  instruments	  worldwide.	  Technology	  transfer	  efforts	  and	  the	  identification	  30	  
of	  appropriate	  regional	  and	  national	  reference	  laboratories	  will	  be	  extremely	  31	  
important	  to	  support	  national	  yaws	  control	  programmes.	  Roll	  out	  of	  new	  techniques	  32	  
8	  
to	  local	  laboratories	  will	  require	  the	  development	  and	  implementation	  of	  1	  
appropriate	  quality	  control	  and	  assessment	  structures.	  2	  
	  3	  
Non-­‐treponemal	  causes	  of	  yaws-­‐like	  lesions	  4	  
	  5	  
The	  differential	  diagnosis	  of	  ulcerative	  lesions	  in	  tropical	  countries	  is	  broad	  and	  6	  
includes	  treponemal	  infections,	  pyoderma	  and	  polymicrobial	  tropical	  ulcers.	  7	  
Haemophilus	  ducreyi	  in	  particular	  has	  now	  been	  shown	  to	  be	  an	  important	  cause	  of	  8	  
ulcerative	  skin	  lesions	  clinically	  similar	  to	  yaws,	  in	  Papua	  New	  Guinea,	  the	  Solomon	  9	  
Islands,	  Vanuatu	  and	  Ghana12,24.	  While	  some	  clinical	  phenotypes—particularly	  bony	  10	  
disease—are	  likely	  to	  be	  more	  yaws-­‐specific,	  the	  clinical	  similarity	  of	  non-­‐yaws	  11	  
lesions	  to	  common	  skin	  manifestations	  of	  yaws	  complicates	  clinical	  case	  reporting	  by	  12	  
national	  surveillance	  programmes13	  and	  highlights	  the	  need	  for	  the	  integration	  of	  13	  
point	  of	  care	  assays	  into	  surveillance	  strategies	  to	  confirm	  suspected	  cases	  of	  yaws.	  	  14	  
	  15	  
An	  additional	  complication	  of	  yaws-­‐like	  ulcers	  that	  should	  be	  considered	  is	  that	  16	  
these	  may	  affect	  community	  perceptions	  of	  the	  efficacy	  of	  azithromycin	  mass	  17	  
treatment.	  Communities	  may	  expect	  mass	  treatment	  to	  be	  a	  solution	  for	  all	  skin	  18	  
diseases	  as	  opposed	  to	  a	  specific	  programme	  targeting	  a	  particular	  pathogen.	  How	  19	  
best	  to	  educate	  communities	  about	  the	  intended	  benefits	  of	  yaws	  eradication	  20	  
programmes	  should	  be	  an	  area	  of	  active	  research	  and	  will	  require	  input	  from	  social	  21	  
scientists	  and	  medical	  anthropologists.	  Integrating	  case	  management	  for	  all	  skin	  22	  
ulcers,	  regardless	  of	  aetiology,	  into	  mass	  treatment	  programmes	  should	  be	  23	  
considered.	  	  24	  
	  25	  
Experimental	  models	  suggest	  that	  azithromycin	  will	  also	  be	  effective	  in	  treating	  non-­‐26	  
genital	  lesions	  caused	  by	  H	  ducreyi29,	  but	  further	  studies	  will	  be	  needed	  to	  evaluate	  27	  
this	  in	  the	  field.	  Data	  from	  pilot	  studies	  of	  community	  mass	  treatment	  for	  yaws	  28	  
eradication	  showed	  that	  the	  absolute	  number	  of	  lesions	  caused	  by	  H.ducreyi	  was	  29	  
also	  reduced,	  although	  not	  as	  markedly	  as	  those	  caused	  by	  T.pallidum	  ssp.	  30	  
pertenue30.	  Consideration	  should	  also	  be	  given	  to	  a	  syndromic	  approach	  to	  skin	  ulcer	  31	  
management,	  integrating	  basic	  skin	  care	  interventions	  such	  as	  provision	  of	  soap	  and	  32	  
9	  
ulcer	  dressings	  alongside	  azithromycin	  mass	  treatment,	  a	  strategy	  likely	  to	  have	  1	  
collateral	  benefits	  for	  both	  community	  engagement	  and	  general	  skin	  health.	  2	  
	  3	  
Treatment	  (Box	  1)	  4	  
	  5	  
Until	  2012,	  long-­‐acting	  injectable	  penicillin	  had	  been	  the	  mainstay	  of	  treatment	  for	  6	  
yaws11.	  A	  landmark	  study	  conducted	  in	  Papua	  New	  Guinea	  showed	  that	  single-­‐dose	  7	  
oral	  azithromycin	  at	  a	  recommended	  dose	  of	  30mg/kg	  (max	  2g)	  was	  equivalent	  to	  8	  
treatment	  with	  penicillin	  in	  both	  primary	  and	  secondary	  yaws5	  with	  a	  clinical	  and	  9	  
serological	  cure	  rate	  of	  95%	  at	  six	  months.	  Treatment	  with	  azithromycin	  is	  now	  10	  
central	  to	  the	  WHO	  eradication	  strategy	  and	  should	  be	  more	  readily	  accepted	  by	  11	  
children	  and	  their	  guardians	  than	  parenteral	  penicillin6.	  	  12	  
	  13	  
The	  current	  WHO	  eradication	  strategy	  is	  initial	  total	  community	  treatment	  with	  14	  
single	  dose	  oral	  azithromycin,	  followed	  by	  subsequent	  resurveys	  with	  targeted	  15	  
treatment	  of	  residual	  cases	  and	  contacts.	  As	  discussed,	  selection	  of	  the	  appropriate	  16	  
treatment	  unit	  will	  be	  important	  to	  make	  this	  strategy	  both	  effective	  and	  efficient.	  In	  17	  
earlier	  campaigns,	  failure	  to	  treat	  contacts	  and	  latent	  cases	  was	  thought	  to	  18	  
contribute	  to	  rapid	  return	  of	  the	  disease31.	  This	  risk	  should	  theoretically	  be	  reduced	  19	  
by	  the	  new	  mass	  treatment	  recommendation.	  	  20	  
	  21	  
Pilot	  studies	  have	  recently	  shown	  that	  implementation	  of	  the	  Morges	  strategy	  22	  
results	  in	  a	  reduction	  of	  clinical	  and	  latent	  cases	  of	  yaws	  and	  may	  potentially	  23	  
interrupt	  transmission30.	  For	  syphilis,	  mass	  treatment	  with	  azithromycin	  was	  shown	  24	  
to	  be	  temporarily	  effective	  in	  reducing	  the	  prevalence	  of	  disease	  in	  high	  risk	  groups32	  25	  
however	  in	  these	  studies,	  syphilis	  subsequently	  rebounded,	  emphasising	  the	  26	  
importance	  of	  follow-­‐up	  treatment	  to	  clear	  infection	  from	  missed	  cases	  and	  27	  
interrupt	  transmission.	  The	  number	  of	  rounds	  of	  mass	  treatment	  and	  the	  coverage	  28	  
required	  to	  interrupt	  transmission	  for	  yaws	  is	  unknown.	  In	  the	  successful	  elimination	  29	  
campaign	  in	  India,	  community	  surveillance	  and	  targeted	  treatment	  were	  performed	  30	  
every	  6	  months	  for	  a	  period	  of	  7	  years33.	  It	  is	  unlikely	  that	  it	  will	  be	  possible	  to	  31	  
conduct	  randomised	  trials	  to	  answer	  the	  questions	  concerning	  coverage	  rates	  and	  32	  
10	  
numbers	  of	  rounds	  of	  treatment	  needed	  to	  eradicate	  yaws.	  Instead,	  observational	  1	  
data	  from	  pilot	  MDA	  programmes	  and	  mathematical	  models	  should	  be	  reviewed	  to	  2	  
frame	  optimal	  community	  treatment	  strategies.	  	  3	  
	  4	  
The	  recommended	  dose	  of	  azithromycin	  for	  patients	  with	  yaws	  is	  30mg/kg	  (max	  2g).	  5	  
A	  major	  disadvantage	  of	  this	  regimen	  is	  the	  relatively	  high	  incidence	  of	  associated	  6	  
gastrointestinal	  adverse	  effects	  of	  around	  15%.	  Azithromycin	  is	  also	  used	  for	  a	  7	  
number	  of	  other	  indications,	  notably	  trachoma,	  at	  a	  lower	  recommended	  dose	  of	  8	  
20mg/kg	  body	  weight	  (max	  1g).	  Lower	  dose	  azithromycin	  is	  likely	  to	  be	  slightly	  better	  9	  
tolerated	  than	  higher	  dose	  treatment.	  Use	  of	  a	  lower	  dose	  could	  confer	  significant	  10	  
cost	  savings	  for	  programmes,	  which	  is	  particularly	  important	  given	  the	  absence	  of	  a	  11	  
current	  drug	  donation	  programme	  for	  yaws	  eradication,	  as	  well	  as	  offering	  synergies	  12	  
for	  countries	  in	  the	  Pacific	  region	  where	  which	  yaws	  and	  trachoma	  are	  co-­‐endemic.	  13	  
As	  three	  of	  the	  four	  most	  heavily	  endemic	  countries	  are	  in	  the	  Pacific,	  this	  could	  be	  14	  
particularly	  beneficial.	  However,	  these	  potential	  benefits	  will	  need	  to	  be	  carefully	  15	  
balanced	  against	  the	  possibility	  of	  the	  development	  of	  drug	  resistance.	  A	  WHO-­‐16	  
sponsored	  trial	  is	  planned	  for	  2015,	  in	  Papua	  New	  Guinea	  and	  Ghana,	  to	  determine	  17	  
whether	  a	  20mg/kg	  dose	  is	  effective	  against	  yaws.	  18	  
	  19	  
Emergence	  of	  macrolide	  resistance	  in	  T.	  pallidum	  subsp	  pertenue,	  which	  has	  already	  20	  
occurred	  with	  T.	  pallidum	  subsp.	  pallidum,	  is	  a	  major	  concern25,34,35.	  Macrolide	  21	  
resistance	  in	  treponemes	  is	  mediated	  by	  point	  mutations	  in	  the	  23S	  rRNA	  22	  
gene23,25,26,36	  and	  is	  associated	  with	  prior	  exposure	  to	  other	  macrolides37.	  23	  
Surveillance	  for	  known	  macrolide	  resistance	  mutations	  in	  a	  very	  limited	  number	  of	  24	  
azithromycin-­‐naïve	  settings	  has	  not	  detected	  any	  azithromycin	  resistant	  yaws	  25	  
strains;	  however,	  close	  monitoring	  after	  mass	  treatment	  will	  be	  vital	  to	  ensure	  the	  26	  
success	  of	  the	  eradication	  strategy.	  27	  
	  28	  
Other	  Considerations	  29	  
	  30	  
Currently,	  human	  yaws	  is	  not	  known	  to	  have	  an	  animal	  reservoir.	  However,	  there	  are	  31	  
a	  considerable	  number	  of	  pathogenic	  T.	  pallidum	  infections	  in	  our	  closest	  relatives,	  32	  
11	  
non-­‐human	  primates	  in	  Africa38–42.	  Both	  asymptomatic	  infection	  and	  clinical	  disease	  1	  
occur	  in	  non-­‐human	  primates.	  All	  the	  currently	  sequenced	  simian	  samples	  are	  2	  
closely	  related	  to	  human	  yaws-­‐causing	  strains38,43.	  	  Experimental	  infection	  of	  humans	  3	  
with	  the	  Fribourg-­‐Blanc	  simian	  strain,44	  and	  reports	  on	  laboratory	  infections	  of	  4	  
nonhuman	  primates	  with	  human	  T.	  pallidum	  isolates40	  suggest	  that	  there	  is	  a	  5	  
theoretical	  potential	  for	  zoonotic	  transmission	  44.	  At	  this	  time	  the	  relevance	  of	  these	  6	  
findings	  to	  the	  yaws	  eradication	  campaign	  remains	  limited,	  but	  further	  study	  is	  7	  
warranted.	  	  8	  
	  9	  
Whilst	  the	  focus	  of	  this	  article	  has	  been	  on	  yaws,	  it	  is	  also	  worth	  remembering	  the	  10	  
two	  other	  endemic	  treponemal	  diseases:	  bejel	  and	  pinta11.	  Available	  data	  on	  these	  11	  
two	  diseases	  are	  even	  more	  limited	  than	  for	  yaws,	  but	  the	  clinical	  and	  12	  
microbiological	  similarities	  among	  the	  diseases	  suggest	  that	  strategies	  developed	  for	  13	  
the	  control	  of	  yaws	  may	  be	  applicable	  more	  broadly.	  Such	  considerations	  should	  be	  14	  
borne	  in	  mind,	  in	  particular	  when	  mapping	  strategies	  are	  formulated,	  so	  that	  15	  
opportunities	  to	  improve	  our	  understanding	  and	  control	  of	  these	  diseases	  are	  also	  16	  
grasped	  where	  feasible.	  	  17	  
	  18	  
Alongside	  the	  research	  questions	  discussed	  in	  this	  article	  there	  are	  a	  large	  number	  of	  19	  
areas	  where	  input	  is	  required	  to	  ensure	  a	  sustained	  and	  effective	  worldwide	  20	  
eradication	  campaign.	  While	  yaws	  eradication	  is	  likely	  to	  be	  a	  cost-­‐effective	  21	  
intervention45,	  there	  is	  a	  need	  to	  secure	  financial	  and	  political	  support	  at	  the	  22	  
national,	  regional	  and	  international	  levels.	  Pilot	  projects	  have	  demonstrated	  the	  23	  
feasibility	  of	  the	  WHO	  strategy	  and	  should	  encourage	  donations	  of	  both	  funds	  and	  24	  
azithromycin.	  As	  well	  as	  financial	  support	  there	  is	  a	  need	  to	  engage	  with	  advocacy	  25	  
groups	  and	  endemic	  communities	  to	  raise	  the	  profile	  of	  yaws	  and	  highlight	  the	  26	  
possibility	  of	  successfully	  eradicating	  the	  disease.	  Links	  to	  other	  NTD	  control	  27	  
programmes	  should	  be	  actively	  sought	  in	  order	  to	  build	  synergies	  at	  all	  stages	  of	  the	  28	  
eradication	  campaign.	  A	  major	  burden	  of	  yaws	  is	  found	  in	  West	  and	  Central	  Africa,	  29	  
which	  has	  recently	  been	  severely	  affected	  by	  the	  Ebola	  epidemic.	  Although	  this	  did	  30	  
not	  predominantly	  affect	  countries	  where	  yaws	  is	  a	  major	  problem,	  the	  regional	  31	  
disruption	  on	  health	  care	  services	  and	  personnel	  caused	  by	  the	  epidemic	  may	  impact	  32	  
12	  
on	  yaws	  eradication	  efforts.	  Finally,	  the	  eradication	  campaign	  must	  develop	  1	  





Considerable	  progress	  has	  been	  made	  in	  the	  last	  three	  years	  in	  developing	  strategies	  7	  
and	  tools	  for	  yaws	  eradication.	  A	  simple,	  cheap	  and	  well	  tolerated	  oral	  treatment	  has	  8	  
been	  demonstrated	  to	  be	  effective,	  point-­‐of-­‐care	  diagnostic	  tests	  have	  been	  9	  
validated	  and	  new	  molecular	  tests	  have	  become	  available.	  Studies	  on	  the	  10	  
epidemiology	  of	  yaws	  and	  pilot	  mass	  treatment	  programmes	  have	  been	  rolled	  out	  in	  11	  
a	  small	  number	  of	  endemic	  countries.	  In	  addition,	  there	  has	  been	  increased	  interest	  12	  
and	  support	  within	  the	  academic	  and	  global	  health	  communities	  for	  yaws	  13	  
eradication	  efforts,	  as	  reflected	  in	  the	  increase	  in	  research	  output	  related	  to	  yaws.	  14	  
The	  WHO	  Morges	  strategy	  represents	  the	  cornerstone	  of	  efforts	  to	  eradicate	  yaws	  15	  
and	  international	  efforts	  should	  be	  focused	  on	  continuing	  to	  roll-­‐out	  this	  strategy	  in	  16	  
the	  known	  endemic	  countries,	  whilst	  simultaneously	  undertaking	  work	  to	  answer	  17	  
the	  research	  questions	  identified.	  Advocacy	  will	  be	  critical	  in	  the	  upcoming	  years	  to	  18	  
transmit	  to	  the	  wider	  public	  health	  community	  the	  importance	  of	  addressing	  this	  19	  
neglected	  disease	  and	  to	  trigger	  concrete	  plans	  for	  action	  towards	  its	  eradication.	  20	  
The	  current	  yaws	  programme	  can	  benefit	  from	  the	  knowledge	  and	  experience	  both	  21	  
of	  past	  yaws	  campaigns	  and	  of	  other	  international	  NTD	  control	  initiatives.	  There	  are	  22	  
considerable	  opportunities	  for	  synergy	  among	  disease	  control	  efforts	  to	  help	  lead	  to	  23	  
a	  sustained	  improvement	  in	  the	  quality	  of	  life	  for	  some	  of	  the	  world’s	  most	  24	  








Table	  1:	  Current	  epidemiology	  of	  yaws	  1	  
	  2	  
	   Number	  of	  cases	  of	  yaws	  reported	   	   	   	  
COUNTRY	   2008	   2009	   2010	   2011	   2012	   2013	  
Benin	   No	  data	   No	  data	   45	   No	  data	   11	   No	  data	  
Côte	  d'Ivoire	   No	  data	   No	  data	   3740	   3343	   3092	   2256	  
Cameroon	   No	  data	   No	  data	   802	   133	   59	   97	  
Central	  African	  Republic	   243	   No	  data	   No	  data	   No	  data	   230	   No	  data	  
Congo	   No	  data	   646	   No	  data	   No	  data	   197	   No	  data	  
Democratic	  Republic	  of	  the	  
Congo	  
383	   No	  data	   No	  data	   No	  data	   No	  
data	  
No	  data	  
Ghana	   20525	   35248	   18157	   9674	   8980	   18702	  
Indonesia	   6083	   7751	   6178	   6631	   4360	   2043	  
Papua	  New	  Guinea	   28989	   25822	   29061	   28989	   17560	   19710	  
Solomon	  Islands	   No	  data	   No	  data	   20635	   No	  data	   12372	   14909	  
Timor-­‐Leste*	   No	  data	   No	  data	   No	  data	   No	  data	   No	  
data	  
No	  data	  
Togo	   No	  data	   No	  data	   15	   No	  data	   No	  
data	  
No	  data	  
Vanuatu	   1972	   2432	   1593	   2331	   2514	   1198	  
Data	  taken	  from	  the	  WHO	  Global	  Observatory	  Data	  Repository46	  3	  
*	  There	  are	  no	  recent	  routine	  reporting	  data	  from	  Timor-­‐Leste,	  but	  reports	  from	  both	  the	  Ministry	  of	  4	  

















































Key	  Research	  Questions	  	  
	  
Epidemiology	  	  	  E1.	  What	  is	  the	  appropriate	  evaluation	  unit	  for	  a	  pre-­‐mass	  treatment	  survey?	  	  E2.	  What	  is	  the	  population	  at	  risk	  and	  distribution	  of	  cases	  in	  the	  13	  known	  endemic	  cases?	  	  E3.	  What	  is	  the	  current	  status	  of	  the	  84	  formerly	  endemic	  countries?	  	  E4.	  Which	  factors	  affect	  the	  spatial	  heterogeneity	  of	  yaws?	  	  Diagnostics	  D1.	  Can	  the	  DPP	  point	  of	  care	  assay	  replace	  traditional	  serology	  for	  all	  phases	  of	  the	  yaws	  eradication	  programme?	  	  D2.	  Can	  we	  develop	  a	  tool	  to	  allow	  diagnosis	  of	  active	  yaws	  from	  a	  dried	  blood	  spot	  –	  facilitating	  integration	  of	  mapping	  activities	  with	  other	  programmes?	  	  D3.	  What	  is	  the	  appropriate	  role	  of	  PCR	  in	  both	  the	  implementation	  and	  post-­‐zero	  cases	  phases	  of	  the	  yaws	  eradication	  programme?	  	  	  
Treatment	  	  	  T1.	  How	  many	  rounds	  of	  mass	  treatment	  should	  be	  undertaken	  to	  interrupt	  transmission?	  	  	  T2.	  Is	  a	  recommended	  dose	  of	  azithromycin	  of	  20mg/kg	  non-­‐inferior	  to	  a	  recommended	  dose	  of	  30mg/kg?	  	  T3.	  Does	  resistance	  to	  azithromycin	  emerge	  in	  Treponema	  pallidum	  subsp	  
pertenue	  following	  mass	  treatment	  ?	  	  T4.	  What	  is	  the	  impact	  of	  community	  mass	  treatment	  with	  azithromycin	  on	  other	  ulcers,	  including	  those	  caused	  by	  Haemophuls	  ducreyi? 
	  T5.	  What	  are	  the	  best	  approaches	  to	  mobilizing	  and	  sustaining	  communities’	  support	  for	  yaws	  eradication?	  	  	  
15	  


























Search	  strategy	  and	  selection	  criteria:	  	  27	  
We	  searched	  pubmed	  using	  the	  terms	  yaws,	  pian,	  treponema	  pallidum.	  Reference	  28	  
lists	  of	  identified	  manuscripts	  were	  reviewed	  to	  identify	  additional	  relevant	  material.	  29	  
We	  reviewed	  literature	  and	  statistics	  held	  at	  the	  World	  Health	  Organization,	  and	  30	  





	  Endemic	  Village	  A	  village	  containing	  at	  least	  1	  indigenous	  confirmed	  case	  
	  Endemic	  Country	  A	  country	  with	  at	  least	  1	  indigenous	  confirmed	  case	  
	  Formerly	  Endemic	  Country	  A	  country	  which	  formerly	  reported	  yaws	  but	  which	  has	  either	  eliminated	  the	  disease	  or	  for	  which	  there	  is	  no	  current	  data	  	  
Implementation	  Unit	  






Suspected	  case	  	  
Individual	  with	  clinical	  signs	  consistent	  with	  yaws	  
	  
Confirmed	  Case 
A	  suspected	  case	  with	  dual	  positive	  serology	  
(either	  DPP	  dually-­‐positive	  or	  TPHA	  +	  RPR	  positive)	  	  
	  
PCR	  may	  be	  used	  during	  the	  implementation	  phase	  to	  monitor	  for	  resistance	  




 Confirmed	  case	  
Suspected	  case	  with	  both	  dual	  positive	  serology	  and	  positive	  PCR	  of	  lesion	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